Literature DB >> 12067631

Molecular insights into Friedreich's ataxia and antioxidant-based therapies.

Agnès Rötig1, Daniel Sidi, Arnold Munnich, Pierre Rustin.   

Abstract

Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disease causing limb and gait ataxia and cardiomyopathy. The disease gene encodes a mitochondrial protein of unknown function, frataxin. The loss of functional frataxin is caused by a large GAA trinucleotide expansion in the first intron of the gene, thus impairing gene transcription. The lack of frataxin appears to result primarily in disabled recruitment of early antioxidant defenses, resulting in oxidative insult to the highly sensitive iron-sulfur proteins aconitase and three mitochondrial respiratory chain complexes (I-III). Accordingly, antioxidant-based therapy appears promising in counteracting the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067631     DOI: 10.1016/s1471-4914(02)02330-4

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  13 in total

Review 1.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

2.  Frataxin, iron-sulfur clusters, heme, ROS, and aging.

Authors:  Eleonora Napoli; Franco Taroni; Gino A Cortopassi
Journal:  Antioxid Redox Signal       Date:  2006 Mar-Apr       Impact factor: 8.401

Review 3.  Small molecules affecting transcription in Friedreich ataxia.

Authors:  Joel M Gottesfeld
Journal:  Pharmacol Ther       Date:  2007-08-09       Impact factor: 12.310

4.  Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management.

Authors:  M Anheim; M Fleury; B Monga; V Laugel; D Chaigne; G Rodier; E Ginglinger; C Boulay; S Courtois; N Drouot; M Fritsch; J P Delaunoy; D Stoppa-Lyonnet; C Tranchant; M Koenig
Journal:  Neurogenetics       Date:  2009-05-14       Impact factor: 2.660

Review 5.  Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease.

Authors:  Hong Ye; Tracey A Rouault
Journal:  Biochemistry       Date:  2010-06-22       Impact factor: 3.162

6.  Pharmacokinetics and metabolism of idebenone in healthy male subjects.

Authors:  Michael Bodmer; Pierre Vankan; Manfred Dreier; Klaus W Kutz; Jürgen Drewe
Journal:  Eur J Clin Pharmacol       Date:  2009-01-06       Impact factor: 2.953

Review 7.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

8.  The effects of idebenone on mitochondrial bioenergetics.

Authors:  Valentina Giorgio; Valeria Petronilli; Anna Ghelli; Valerio Carelli; Michela Rugolo; Giorgio Lenaz; Paolo Bernardi
Journal:  Biochim Biophys Acta       Date:  2011-11-04

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

10.  Redox processes in neurodegenerative disease involving reactive oxygen species.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.